08-Apr-2020 - HeiQ Materials AG

Antiviral treatment for textiles

An ETH spin-​off has developed a new treatment for textiles that reduces viral infectivity on treated surfaces. The technology can be used for face masks and other textile products.

Recently, the ETH spin-​off HeiQ Materials presented an innovative antiviral and antibacterial treatment for textiles, which has been tested effectively against coronavirus, for example. The technology can be used for products such as face masks. The company has not yet carried out a direct test regarding the treatment’s efficacy against the current pandemic virus SARS-​CoV-2. However, they have tested it using another type of coronavirus (229E), which has circulated in people worldwide for years and causes colds, and which is highly similar to the membrane structure of SARS-​CoV-2. In the test, the treated face masks reduced the number of infectious 229E virus particles 10,000-​fold.

The technology is already scheduled to be used in the production of face masks from the start of April, as HeiQ announced in a press release. The first customers include a Chinese protective mask manufacturer. Other companies are also planning to use the technology for other textile products, such as protective gloves. According to HeiQ, other application areas include protective clothing for medical staff, air filters and curtains. The treatment can be used on all types of textile fibres. The viruses that are deactivated include those with a lipid envelope, such as coronaviruses. In the test, the technology not only proved effective against the human coronavirus 229E, but also against various kinds of influenza viruses. "Our goal is to prevent textiles from becoming a host surface for propagating harmful viruses and bacteria, and contribute to reduce the risk and speed of contamination and transmission”, explains Carlo Centonze, CEO of HeiQ.

Facts, background information, dossiers
  • protective clothing
More about ETH Zürich
  • News

    Using electrical stimulus to regulate genes

    A team of researchers led by ETH professor Martin Fussenegger has succeeded in using an electric current to directly control gene expression for the first time. Their work provides the basis for medical implants that can be switched on and off using electronic devices outside the body. This ... more

    Lighting the path for cells

    ETH researchers have developed a new method in which they use light to draw patterns of molecules that guide living cells. The approach allows for a closer look at the development of multicellular organisms – and in the future may even play a part in novel therapies.  Highly complex organis ... more

    Prostate cancer treatment may protect from COVID-19

    Androgen-​deprivation therapy could protect against infection with SARS-​CoV-2 and against severe disease progression. This is suggested by a study led by a professor from the Università della Svizzera Italiana and ETH Zurich. Male cancer patients have a 1.8-​fold increased risk of COVID-​1 ... more